Evidence map›Paper›PMID 38760387›Full record

ArticleScientific reports2024

Radiomic profiles improve prognostication and reveal targets for therapy in cervical cancer.

Mari Kyllesø Halle, Erlend Hodneland, Kari S Wagner-Larsen, Njål G Lura, Kristine E Fasmer, Hege F Berg, Tomasz Stokowy, Aashish Srivastava, David Forsse, Erling A Hoivik and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07305727 (Developing a Radiomic MRI Model Predictive of Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer. A Prognostic, Retrospective, Open-label, Multicenter, Descriptive and Analytical Clinical Cohort Study), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07305727 recruitingnot on this mapstarted 2026, after this paper: background citation

Developing a Radiomic MRI Model Predictive of Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer. A Prognostic, Retrospective, Open-label, Multicenter, Descriptive and Analytical Clinical Cohort Study

TypeobservationalSponsorCentre Hospitalier Universitaire de NīmesRan2026 to 2026Enrolled120ConditionsUterine Cervical Neoplasms, Cervical Cancer by FIGO Stage 2018
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mari Kyllesø Halle *Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Erlend Hodneland *Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Kari S Wagner-LarsenMohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Njål G LuraMohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Kristine E FasmerMohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Hege F BergCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Tomasz StokowyGenomics Core Facility, Department of Clinical Science, University of Bergen, Bergen, Norway.
Aashish SrivastavaGenomics Core Facility, Department of Clinical Science, University of Bergen, Bergen, Norway.
David ForsseCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Erling A HoivikCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Kathrine WoieDepartment of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.
Bjørn I BertelsenDepartment of Pathology, Haukeland University Hospital, Bergen, Norway.
Camilla KrakstadCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway. camilla.krakstad@uib.no.
Ingfrid S HaldorsenMohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway. ingfrid.helene.salvesen.haldorsen@helse-bergen.no.

Funding

Bergens Forskningsstiftelse BFS2018TMT06Helse Vest F-12542Helse Vest HV912263Kreftforeningen 104484Kreftforeningen 190202Norges forsknigsråd 311350Norges Forskningsråd 326348Trond Mohn stiftelse 809119
6 · The paper itself

Abstract

Cervical cancer (CC) is a major global health problem with 570,000 new cases and 266,000 deaths annually. Prognosis is poor for advanced stage disease, and few effective treatments exist. Preoperative diagnostic imaging is common in high-income countries and MRI measured tumor size routinely guides treatment allocation of cervical cancer patients. Recently, the role of MRI radiomics has been recognized. However, its potential to independently predict survival and treatment response requires further clarification. This retrospective cohort study demonstrates how non-invasive, preoperative, MRI radiomic profiling may improve prognostication and tailoring of treatments and follow-ups for cervical cancer patients. By unsupervised clustering based on 293 radiomic features from 132 patients, we identify three distinct clusters comprising patients with significantly different risk profiles, also when adjusting for FIGO stage and age. By linking their radiomic profiles to genomic alterations, we identify putative treatment targets for the different patient clusters (e.g., immunotherapy, CDK4/6 and YAP-TEAD inhibitors and p53 pathway targeting treatments).

Indexed as

Magnetic Resonance ImagingUterine Cervical NeoplasmsAdultAgedFemaleHumansMiddle AgedPrognosisRadiomicsRetrospective StudiesCluster analysisImaging genomicsMagnetic resonance imagingMolecular targeted treatmentUterine cervical neoplasms

Identifiers

PMID38760387
PMCPMC11101482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.